Skip to main content
. 2019 Mar 30;8(1):17–25. doi: 10.14740/jh471

Figure 3.

Figure 3

VTE rate by low risk (< 3) and high risk (≥ 3) Khorana score in pancreatic (a), endometrial (b), colorectal (c) and ovarian (d) cancer patients. Cervical cancer cohort not included as no VTE events. High risk Khorana score predicted VTE in endometrial cancer (VTE rate high-risk Khorana: 4/24 (16.7%) vs. low-risk: 2/130 (1.5%); P < 0.001) but not in other cancer groups.